Bjerre

About Steen Bjerre

This author has not yet filled in any details.
So far Steen Bjerre has created 90 blog entries.

Change to Pharming strategy now bearing fruit

From the Pharming Group N.V. financial report for the first quarter ended 31 March 2016: During the quarter we initiated sales of Ruconest in the countries which Pharming now commercializes directly, in Germany, Austria and the Netherlands . These countries had proved very difficult for our partner SOBI prior to 2015 when we agreed to take [...]

CSL Behring Commemorates 2016 hae day :-)

CSL Behring joins the global HAE community today in recognition of the fifth annual hae day :-), an initiative led by HAEi, the international patient organization for C1-inhibitor deficiency, along with the support of its national member organizations, including the US Hereditary Angioedema Association (HAEA). HAE Day is a global awareness event that aims to support [...]

Pharming Group Supports HAE DAY :-) 2016

Pharming Group N.V. supports the Fifth Annual International Hereditary Angioedema Day, hae day :-) taking place on 16 May 2016 and aiming to raise awareness around HAE. hae day :-) is coordinated by the HAEi, the International Patient Organization for C1-Inhibitor Deficiency, along with direct support of its Member Organizations and encourages patient organizations from across the globe [...]

Working through the start-up activities

  "We are currently working through the start-up activities for the APeX-1 trial of BCX7353 for prevention of angioedema attacks in HAE patients and are targeting the end of the year to report results," said Jon P. Stonehouse, President & CEO of BioCryst Pharmaceuticals, Inc. "In addition, we are conducting a Phase 1 clinical pharmacology study in [...]

HAEi Newsletter #2/2016 out now

We are excited to inform you that the second edition of the 2016 newsletter is out now. Again, the newsletter offers our readers either a "Magazine View" og a "Single Page View". Feel free to download it here.  

Join the global HAE Walk

  Quite a number of people have told HAEi that they would really have liked to be with us in northern Spain but are unable for one reason or the other. Therefore we have arranged a global HAE walk. It works in this very simple way: You can participate wherever you are. All you need [...]

Raising awareness step by step on the Camino

80 people – most of them suffering from a rare and potentially fatal disease – will meet mid-May in northern Spain in order to walk part of the legendary Camino de Santiago together. The patients all suffer from Hereditary Angioedema (HAE) and it is far from an everyday occurrence to walk the kind of mileage [...]

Change in Marketing Authorization Terms For Ruconest

The European Commission has adopted the CHMP recommendation to include the treatment of HAE attacks in adolescents with HAE and to remove the requirements for rabbit IgE testing that formed part of the EU label for Ruconest. The CHMP also noted that the importance of favorable effects of Ruconest is further supported by the continued availability [...]

Shire 2015 Annual Report

HAE related information from the Shire plc 2015 Annual Report: The $6 billion acquisition of Dyax expands and extends our industry-leading portfolio in HAE. With Dyax we bring into our portfolio DX-2930 (now SHP643). If approved, this therapy has the potential to expand HAE-treated patients and achieve worldwide sales of up to $2 billion with [...]

Global Blood Therapeutics Reports Recent Business Progress

Global Blood Therapeutics, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, has reported business progress and financial results for the fourth quarter and year ended December 31, 2015. Among the "2016 Anticipated Milestones" you will find: Hereditary Angioedema: Complete IND-enabling toxicology studies, submit an IND, and initiate [...]